Press Releases on September 14, 2024 - EIN Presswire - Press Release Distribution Service

Published on September 14, 2024 - 07:05 GMT

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors ...

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to modulate the tumor microenvironment, …

Distribution channels: Media, Advertising & PR ...

Published on September 14, 2024 - 07:05 GMT

Le virus oncolytique BT-001 de Transgene et BioInvent montre une activité antitumorale prometteuse dans l’étude en cours de Phase ...

Les premières données cliniques présentées à l’ESMO 2024 montrent que BT-001 induit une diminution de la taille des tumeurs chez des patients en échec thérapeutique Chez un patient atteint d’un sarcome lourdement prétraité, BT-001 a la capacité de …

Distribution channels: Media, Advertising & PR ...

Published on September 14, 2024 - 07:01 GMT

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma ...

BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on September 14, 2024 - 07:00 GMT

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with chemotherapy in heavily pre-treated, platinum-resistant ovarian …

Distribution channels: Technology ...

Published on September 14, 2024 - 07:00 GMT

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating ...

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication …

Distribution channels: Media, Advertising & PR, Technology ...

Published on September 14, 2024 - 07:00 GMT

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 …

Distribution channels: Technology ...

Published on September 14, 2024 - 06:30 GMT

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck ...

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals or Added Systemic Safety Concerns Observed -- -- Data …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on September 14, 2024 - 06:30 GMT

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES ...

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on September 14, 2024 - 06:16 GMT

Traffic Alert - VT RT 100 Newport Town

State of Vermont Department of Public Safety Vermont State Police - Derby Press Release – Highway / Traffic Notification VT Route 100 at the intersection of VT Route 114 in Newport Town is closed in the area of 945 VT Route 100 due to a structure …

Distribution channels:

Published on September 14, 2024 - 06:16 GMT

Fw: Traffic Alert - VT RT 100 Newport Town - CORRECTION

CORRECTION - State of Vermont Department of Public Safety Vermont State Police - Derby Press Release – Highway / Traffic Notification VT Route 100 at the intersection of VT Route 14 in Newport Town is closed in the area of 945 VT Route 100 due to a …

Distribution channels: